Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts

Emily S. Van Laar, E. Izbicka, S. Weitman, L. Medina-Gundrum, J. R. MacDonald, S. J. Waters

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The objective of this study was to investigate the cytotoxic activity of irofulven (HMAF, MGI 114), a unique chemotherapeutic agent currently under clinical investigation, in various preclinical models of ovarian cancer. Antiproliferative effects of irofulven in ovarian cancer cell lines and ovarian tumor specimens were characterized in vitro using sulforhodamine B and human tumor colony-forming assays, respectively. Irofulven demonstrated marked activity against a panel of ovarian tumor cell lines, including IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SK-OV-3, all of which exhibit various drug resistance mechanisms. In human tumor cloning assays, irofulven inhibited colony formation in surgically derived ovarian tumors at concentrations as low as 0.001 μg/ml and indicated superior activity in comparison with paclitaxel when tested against the same tumor specimens. The antitumor activity of irofulven compared to that of paclitaxel was also examined using the SK-OV-3 xenograft model. In mice bearing subcutaneously implanted SK-OV-3 tumors, treatment with paclitaxel failed to inhibit tumor growth; whereas mice treated with maximum tolerated doses of irofulven had a 25% partial shrinkage rate, and the remaining animals had a mean tumor growth inhibition of 82%. The potent activity of irofulven against ovarian tumors in vitro and in vivo supports the evaluation of its clinical activity in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)824-831
Number of pages8
JournalInternational Journal of Gynecological Cancer
Issue number5
StatePublished - Sep 1 2004


  • Drug resistance
  • HMAF
  • Preclinical

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts'. Together they form a unique fingerprint.

Cite this